ReviewFrontiers in immunology2026
Multidimensional regulation of hepatic macrophages in chronic liver disease: from metabolic reprogramming to intercellular and interorgan crosstalk.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver diseases (CLDs), including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD, viral hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)), impose enormous global public health burdens. Hepatic macrophages act as core orchestrators governing the initiation and progression of all CLD subtypes. This review systematically integrates recent advances regarding hepatic macrophage ontogeny, spatial heterogeneity, metabolic rewiring, multi-cellular communication, and systemic neuro-immune crosstalk along the gut-liver-brain axis. Beyond the outdated binary M1/M2 classification, tissue-resident macrophages (ResMø) and recruited monocyte-derived macrophages (MDMs) differentiate into disease-specific subsets (LAMs, SAMs, SenAMs) with spatially restricted, context-dependent functions. Metabolic reprogramming-glycolysis for pro-inflammatory polarization versus oxidative phosphorylation (OXPHOS)/fatty acid oxidation (FAO) for tissue-repair phenotypes-serves as the intrinsic molecular switch shaping macrophage effector profiles. Extrinsically, bidirectional signaling between hepatic macrophages and hepatocytes, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs), and other intrahepatic immune cells dictates the balance between hepatic injury and tissue regeneration. Macrophage-derived autophagy, LC3-associated phagocytosis (LAP), and exosomal cargo transfer represent pivotal functional executors mediating intercellular signal transmission. Furthermore, gut microbial metabolites and bidirectional liver-brain neuroimmune signals converge on hepatic macrophages, linking local hepatic inflammation to systemic metabolic and neurocognitive complications. This review further summarizes unresolved bottlenecks and translational prospects for macrophage-targeted precision therapy. Collectively, these multi-layered regulatory networks provide a comprehensive theoretical framework for identifying novel therapeutic targets across the full spectrum of CLDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.